Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frances A Collichio

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
American Journal of Surgery|October 12, 2004
High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancerNancy Klauber-Demore, Cherie Kuzmiak, Erika L Rager, et al.
The American Journal of Surgical Pathology|January 13, 2026
Prognostic Value of a Novel Nuclear Grading of Cutaneous Melanoma: The UNC Chapel Hill MethodSarah G McAlpine, Shantanu Srivatsa, Paige C Jones, et al.
Frontiers in Oncology|February 8, 2021
Brain Tumor Microenvironment and Angiogenesis in Melanoma Brain MetastasesDimitri G Trembath, Eric S Davis, Shanti Rao, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 19, 2023
Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast TumorsBenjamin G Vincent, Danielle M File, Karen P McKinnon, et al.
BMC Cancer|January 6, 2022
The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanomaGeorgia Sofia Karachaliou, Rached Alkallas, Sarah B Carroll, et al.
Oncoimmunology|May 1, 2023
Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanomaJorge D Oldan, Benjamin C Giglio, Eric Smith, et al.
Melanoma Research|March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.
Journal of Neuro-Oncology|February 9, 2026
Symptomatic radiation necrosis after concurrent targeted therapy and stereotactic radiosurgery for brain metastases: a bicentric retrospective analysisEthan M Steele, Jacob T Hall, Kevin Lui, et al.
Frontiers in Oncology|January 22, 2019
The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous MelanomaXiaobei Zhao, Paul Little, Alan P Hoyle, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
American Journal of Surgery|October 12, 2004
High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancerNancy Klauber-Demore, Cherie Kuzmiak, Erika L Rager, et al.
The American Journal of Surgical Pathology|January 13, 2026
Prognostic Value of a Novel Nuclear Grading of Cutaneous Melanoma: The UNC Chapel Hill MethodSarah G McAlpine, Shantanu Srivatsa, Paige C Jones, et al.
Frontiers in Oncology|February 8, 2021
Brain Tumor Microenvironment and Angiogenesis in Melanoma Brain MetastasesDimitri G Trembath, Eric S Davis, Shanti Rao, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 19, 2023
Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast TumorsBenjamin G Vincent, Danielle M File, Karen P McKinnon, et al.
BMC Cancer|January 6, 2022
The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanomaGeorgia Sofia Karachaliou, Rached Alkallas, Sarah B Carroll, et al.
Oncoimmunology|May 1, 2023
Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanomaJorge D Oldan, Benjamin C Giglio, Eric Smith, et al.
Melanoma Research|March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.
Journal of Neuro-Oncology|February 9, 2026
Symptomatic radiation necrosis after concurrent targeted therapy and stereotactic radiosurgery for brain metastases: a bicentric retrospective analysisEthan M Steele, Jacob T Hall, Kevin Lui, et al.
Frontiers in Oncology|January 22, 2019
The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous MelanomaXiaobei Zhao, Paul Little, Alan P Hoyle, et al.
Pageof 5